wikidoc - Recent changes [en]

GGC triplet gene transcriptions

2026-04-25T08:13:04Z

GGC samplings

← Older revision		Revision as of 08:13, 25 April 2026
Line 440:		Line 440:

	==GGC samplings==		==GGC samplings==
			[[GGC triplet gene transcriptions#GGC samplings\|GGC samplings]]

	Copying a responsive elements consensus sequence GGC and putting the sequence in "⌘F" finds 145 + 57 between ZNF497 and A1BG or 17 + 121 between ZSCAN22 and A1BG as can be found by the computer programs.		Copying a responsive elements consensus sequence GGC and putting the sequence in "⌘F" finds 145 + 57 between ZNF497 and A1BG or 17 + 121 between ZSCAN22 and A1BG as can be found by the computer programs.

Datopotamab deruxtecan-dlnk

2026-04-25T05:40:10Z

Show changes

Datopotamab deruxtecan-dlnk

2026-04-25T03:20:50Z

Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=DATROWAY |aOrAn=a |drugClass=Trop-2-directed antibody and topoisomerase inhibitor conjugate |indicationType=treatment |indication=DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: 1. Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) DATROWAY is indicated for the treatment of adult patients with locally advanced or metastati..."

Show changes

GGC triplet gene transcriptions

2026-04-24T08:54:17Z

GGCGGC triplet samplings

← Older revision		Revision as of 08:54, 24 April 2026
Line 260:		Line 260:

	==GGCGGC triplet samplings==		==GGCGGC triplet samplings==
			[[GGC triplet gene transcriptions#GGCGGC triplet samplings\|GGCGGC triplet samplings]]

	# Negative strand, negative direction, looking for GGCGGC, 0.		# Negative strand, negative direction, looking for GGCGGC, 0.

Gcn4p gene transcriptions

2026-04-23T20:46:21Z

Gcn4p binding site (Tang) samplings

← Older revision		Revision as of 20:46, 23 April 2026
Line 27:		Line 27:

	==Gcn4p binding site (Tang) samplings==		==Gcn4p binding site (Tang) samplings==
			[[Gcn4p gene transcriptions#Gcn4p binding site (Tang) samplings\|Gcn4p binding site (Tang) samplings]]

	Copying ATGACTC in "⌘F" yields none between ZNF497 and A1BG on the negative strand.		Copying ATGACTC in "⌘F" yields none between ZNF497 and A1BG on the negative strand.

Hypertension

2026-04-23T14:37:46Z

Modified the treatment section in line with the 2025 AHA/ACC guidelines for the management of hypertension

← Older revision		Revision as of 14:37, 23 April 2026
(2 intermediate revisions by the same user not shown)
Line 1:		Line 1:
	__NOTOC__		__NOTOC__
	{{SI}}		{{SI}}
	{{CMG}}; {{AE}} {{Sara.Zand}} {{USAMA}}		{{CMG}}; {{AE}} {{Sara.Zand}} {{USAMA}} {{HMA}}

	{{SK}} Blood pressure; hypertension; high blood pressure; systolic blood pressure; essential hypertension		{{SK}} Blood pressure; hypertension; high blood pressure; systolic blood pressure; essential hypertension
Line 858:		Line 858:
	:*[[Renin-angiotensin-convertng enzyme inhibitors]] ([[ACEI]] or [[ARB]])		:*[[Renin-angiotensin-convertng enzyme inhibitors]] ([[ACEI]] or [[ARB]])
	:*[[Thiazide-like diuretic]]		:*[[Thiazide-like diuretic]]
	::*~~[[Betablocker]] is~~ first line ~~therapy in the presence of~~ [[~~angina~~]] ~~and [[~~heart failure]].		::*Beta-blockers are not first-line for hypertension unless specific comorbidities (e.g., [[coronary heart disease]], heart failure with reduced ejection fraction) are present.
	::*Second-line lowering [[BP]] agents are used in resistant [[hypertension]] or specific conditions.		::*Second-line lowering [[BP]] agents are used in resistant [[hypertension]] or specific conditions

			* For Stage 2 hypertension (BP ≥140/90 mm Hg), initiation of antihypertensive therapy with two first-line agents of different classes, ideally in a single-pill combination, is recommended to improve blood pressure control and medication adherence.

	*The mainstay of therapy for [[resistant hypertension]] is:		*The mainstay of therapy for [[resistant hypertension]] is:
Line 865:		Line 867:
	:*Improving medications adherence		:*Improving medications adherence
	:*Diagnosis and treatment of the causes of [[secondary hypertension]]		:*Diagnosis and treatment of the causes of [[secondary hypertension]]
	:*Adding [[spironolactone]] or [[hydralazine]] or [[ minoxidil]] to first line therapy ([[CCB]]s, [[inhibitors of RAS]], [[chlorthalidone]].		:*Adding [[spironolactone]] or [[hydralazine]] or [[ minoxidil]] to first line therapy ([[CCB]]s, [[inhibitors of RAS]], [[chlorthalidone]]).
			:*Renal Denervation may be reasonable as an adjunct in select patients

	{{familytree/start}}		{{familytree/start}}
Line 874:		Line 877:
	{{familytree \| B01 \| \| \| B02 \| \| \| \| \| B03 \| \| \| \|B04\| \|B01=Nomal [[BP]] ([[BP]]<120/80 mmHg)\|B02=Elevated [[BP]] ([[BP]]120-129/<80mmHg)\|B03=Stage1 [[hypertension]](BP 130-139/80-89mmHg\|B04=Stage 2 [[hypertension]] ([[BP]]≥ 140/90}}		{{familytree \| B01 \| \| \| B02 \| \| \| \| \| B03 \| \| \| \|B04\| \|B01=Nomal [[BP]] ([[BP]]<120/80 mmHg)\|B02=Elevated [[BP]] ([[BP]]120-129/<80mmHg)\|B03=Stage1 [[hypertension]](BP 130-139/80-89mmHg\|B04=Stage 2 [[hypertension]] ([[BP]]≥ 140/90}}
	{{familytree \| \|!\| \| \| \| \|!\| \| \| \| \| \| \|!\| \| \| \| \|!\| }}		{{familytree \| \|!\| \| \| \| \|!\| \| \| \| \| \| \|!\| \| \| \| \|!\| }}
	{{familytree \| C01 \| \| \| C02 \| \| \| \| \| C03 \| \| \| \|C04\| \|C01=Life style modifications\|C02=Nonpharmocological therapy (class1)\|C03= 10 ~~years~~ cardiovascular disease ([[CVD]]) ~~risk≥ 10~~%\|C04=Non pharmacological therapy and [[BP]]lowering medication}}		{{familytree \| C01 \| \| \| C02 \| \| \| \| \| C03 \| \| \| \|C04\| \|C01=Life style modifications\|C02=Nonpharmocological therapy (class1)\|C03= 10-year cardiovascular disease (CVD) risk ≥7.5% by PREVENT\|C04=Non pharmacological therapy and [[BP]]lowering medication}}
	{{familytree \| \|!\| \| \| \| \|!\| \| \| \| \|,\|-\|^\|-\|.\| \| \|!\| \| \| \| \| \| \| \| \|}}		{{familytree \| \|!\| \| \| \| \|!\| \| \| \| \|,\|-\|^\|-\|.\| \| \|!\| \| \| \| \| \| \| \| \|}}
	{{familytree \| \|D01\| \| \| D02 \| \| \| D03 \| \| D04 \|!\| \| \| \| \| \| \| D01=Reevaulation in 1 year (class 2a)\|D02=Reevaulation in 3-6 months (class 1)\|D03= NO, nonpharmocological therapy (class1)\|D04= Yes,non pharmacological therapy and [[BP]] lowering medication}}		{{familytree \| \|D01\| \| \| D02 \| \| \| D03 \| \| D04 \|!\| \| \| \| \| \| \| D01=Reevaulation in 1 year (class 2a)\|D02=Reevaulation in 3-6 months (class 1)\|D03= NO, nonpharmocological therapy (class1)\|D04= Yes,non pharmacological therapy and [[BP]] lowering medication}}
Line 1,217:		Line 1,220:

	*[[Surgery\|Surgical]] procedure may be performed for patients with [[secondary hypertension]] such as [[coarctation of aorta]], [[Primary aldosteronism\|primary aldosteronism.]]		*[[Surgery\|Surgical]] procedure may be performed for patients with [[secondary hypertension]] such as [[coarctation of aorta]], [[Primary aldosteronism\|primary aldosteronism.]]
			*Renal Denervation may be reasonable as an adjunct in select patients with resistant hypertension or drug intolerance, but requires evaluation by a multidisciplinary team.

	===Prevention===		===Prevention===
Line 1,222:		Line 1,226:
	*Effective measures for the [[primary prevention]] of hypertension include: <ref name="WheltonCarey2018">{{cite journal\|last1=Whelton\|first1=Paul K.\|last2=Carey\|first2=Robert M.\|last3=Aronow\|first3=Wilbert S.\|last4=Casey\|first4=Donald E.\|last5=Collins\|first5=Karen J.\|last6=Dennison Himmelfarb\|first6=Cheryl\|last7=DePalma\|first7=Sondra M.\|last8=Gidding\|first8=Samuel\|last9=Jamerson\|first9=Kenneth A.\|last10=Jones\|first10=Daniel W.\|last11=MacLaughlin\|first11=Eric J.\|last12=Muntner\|first12=Paul\|last13=Ovbiagele\|first13=Bruce\|last14=Smith\|first14=Sidney C.\|last15=Spencer\|first15=Crystal C.\|last16=Stafford\|first16=Randall S.\|last17=Taler\|first17=Sandra J.\|last18=Thomas\|first18=Randal J.\|last19=Williams\|first19=Kim A.\|last20=Williamson\|first20=Jeff D.\|last21=Wright\|first21=Jackson T.\|title=2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines\|journal=Hypertension\|volume=71\|issue=6\|year=2018\|issn=0194-911X\|doi=10.1161/HYP.0000000000000065}}</ref>		*Effective measures for the [[primary prevention]] of hypertension include: <ref name="WheltonCarey2018">{{cite journal\|last1=Whelton\|first1=Paul K.\|last2=Carey\|first2=Robert M.\|last3=Aronow\|first3=Wilbert S.\|last4=Casey\|first4=Donald E.\|last5=Collins\|first5=Karen J.\|last6=Dennison Himmelfarb\|first6=Cheryl\|last7=DePalma\|first7=Sondra M.\|last8=Gidding\|first8=Samuel\|last9=Jamerson\|first9=Kenneth A.\|last10=Jones\|first10=Daniel W.\|last11=MacLaughlin\|first11=Eric J.\|last12=Muntner\|first12=Paul\|last13=Ovbiagele\|first13=Bruce\|last14=Smith\|first14=Sidney C.\|last15=Spencer\|first15=Crystal C.\|last16=Stafford\|first16=Randall S.\|last17=Taler\|first17=Sandra J.\|last18=Thomas\|first18=Randal J.\|last19=Williams\|first19=Kim A.\|last20=Williamson\|first20=Jeff D.\|last21=Wright\|first21=Jackson T.\|title=2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines\|journal=Hypertension\|volume=71\|issue=6\|year=2018\|issn=0194-911X\|doi=10.1161/HYP.0000000000000065}}</ref>

	:*[[Weight loss]]: ~~Reduction 1 mmHg~~ in ~~[[blood pressure]] for every one kilogram [[~~weight reduction]]		:*Weight loss: Sustained ≥5% reduction in body weight or ≥3 kg/m² reduction in BMI. Expect ~1 mmHg SBP drop per 1 kg lost
	:*[[Healthy diet]]: A [[diet]] rich in [[fruits]], [[vegetables]], [[whole grains]], [[low-fat dairy products]], reduced content of saturated and [[total fat]]		:*[[Healthy diet]]: A [[diet]] rich in [[fruits]], [[vegetables]], [[whole grains]], [[low-fat dairy products]], reduced content of saturated and [[total fat]]
	:*[[Reduced]] intake of dietary [[sodium]]: ~~Less than 1000-15000~~ mg/day		:*Reduced intake of dietary sodium: Target <2300 mg/day, with ideal limit <1500 mg/day
	:*Enhanced intake of [[dietary~~]][[~~ potassium]]:3500–5000 mg/d by intaking rich diet with [[~~potassium~~]]		:*Enhanced intake of dietary potassium: 3500–5000 mg/d by ideally intaking rich diet with potassium, or moderate supplementation (<80 mmol/day)
			:*Use of salt substitutes: Replace regular table/cooking salt with potassium-based salt substitutes. Avoid in [[CKD]] or with potassium-sparing drugs
			:*Reduced alcohol intake: Abstinence is optimal for BP control. If consumed, reduce intake by >50% to ≤1 drink/day for women or ≤2 drinks/day for men
	:*[[Physical activity]]: [[Aerobic]] ( 90–150 min/week), dynamic resistance (90–150 min/week), [[Isometric exercise\|Isometric]] resistance (4 × 2 min handgrip, 1 min rest between exercises, 3 sessions per week)		:*[[Physical activity]]: [[Aerobic]] ( 90–150 min/week), dynamic resistance (90–150 min/week), [[Isometric exercise\|Isometric]] resistance (4 × 2 min handgrip, 1 min rest between exercises, 3 sessions per week)
	:*~~Reduced [[alcohol]] intake~~: ~~Men ≤2 drinks daily, Women ≤1 drink daily~~		:*Stress reduction: Transcendental meditation (2 × 20 min/day) or device-guided slow breathing (<10 breaths/min for 15 min/day) may be reasonable adjuncts to lifestyle modification

	*Once diagnosed and treated, patients with hypertension are followed-up every month for evaluation of medication adherence and response to treatment.		*Once diagnosed and treated, patients with hypertension are followed-up every month for evaluation of medication adherence and response to treatment.

			=== Treatment Goal ===
			For all adults with confirmed hypertension, the recommended target is <130/80 mm Hg. For high-risk patients (10-year CVD risk ≥7.5% by PREVENT), achieving SBP <120 mm Hg is encouraged to reduce major adverse events.

	==References==		==References==

Gcn4p gene transcriptions

2026-04-23T09:28:46Z

GCRE samplings

← Older revision		Revision as of 09:28, 23 April 2026
Line 71:		Line 71:

	==GCRE samplings==		==GCRE samplings==
			[[Gcn4p gene transcriptions#GCRE samplings\|GCRE samplings]]

	For the Basic programs testing consensus sequence TGA(C/G/T)T(A/C/G)(A/T) (starting with SuccessablesGcn4.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:		For the Basic programs testing consensus sequence TGA(C/G/T)T(A/C/G)(A/T) (starting with SuccessablesGcn4.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:
	# negative strand, negative direction, looking for TGA(C/G/T)T(A/C/G)(A/T), 2, TGAGTCT at 3644, TGACTAT at 3544~~, and complements~~.		# negative strand, negative direction, looking for TGA(C/G/T)T(A/C/G)(A/T), 2, TGAGTCT at 3644, TGACTAT at 3544.
	# ~~negative~~ strand, ~~positive~~ direction, looking for TGA(C/G/T)T(A/C/G)(A/T), 5, ~~TGATTAT~~ at ~~4165~~, ~~TGATTAT~~ at ~~4158~~, ~~TGAGTGA~~ at ~~3712, TGAGTGT at 3592, TGATTGT at 2678, and complements~~.		# positive strand, negative direction, looking for TGA(C/G/T)T(A/C/G)(A/T), 3, TGAGTAT at 3829, TGACTCT at 2788, TGAGTCT at 278.
	# ~~positive~~ strand, ~~negative~~ direction, looking for TGA(C/G/T)T(A/C/G)(A/T), 3, ~~TGAGTAT~~ at ~~3829~~, ~~TGACTCT~~ at ~~2788~~, ~~TGAGTCT~~ at ~~278~~, ~~and complements~~.		# negative strand, positive direction, looking for TGA(C/G/T)T(A/C/G)(A/T), 5, TGATTAT at 4165, TGATTAT at 4158, TGAGTGA at 3712, TGAGTGT at 3592, TGATTGT at 2678.
	# positive strand, positive direction, looking for TGA(C/G/T)T(A/C/G)(A/T), 2, TGAGTGA at 4338, TGACTAA at 2676~~, and complements~~.		# positive strand, positive direction, looking for TGA(C/G/T)T(A/C/G)(A/T), 2, TGAGTGA at 4338, TGACTAA at 2676.
	# complement, negative strand, negative direction, looking for ACT(A/C/G)A(C/G/T)(A/T), 3, ACTCATA at 3829, ACTGAGA at 2788, ACTCAGA at 278.		# complement, negative strand, negative direction, looking for ACT(A/C/G)A(C/G/T)(A/T), 3, ACTCATA at 3829, ACTGAGA at 2788, ACTCAGA at 278.
			# complement, positive strand, negative direction, looking for ACT(A/C/G)A(C/G/T)(A/T), 2, ACTCAGA at 3644, ACTGATA at 3544.
	# complement, negative strand, positive direction, looking for ACT(A/C/G)A(C/G/T)(A/T), 2, ACTCACT at 4338, ACTGATT at 2676.		# complement, negative strand, positive direction, looking for ACT(A/C/G)A(C/G/T)(A/T), 2, ACTCACT at 4338, ACTGATT at 2676.
	~~# complement, positive strand, negative direction, looking for ACT(A/C/G)A(C/G/T)(A/T), 2, ACTCAGA at 3644, ACTGATA at 3544.~~
	# complement, positive strand, positive direction, looking for ACT(A/C/G)A(C/G/T)(A/T), 5, ACTAATA at 4165, ACTAATA at 4158, ACTCACT at 3712, ACTCACA at 3592, ACTAACA at 2678.		# complement, positive strand, positive direction, looking for ACT(A/C/G)A(C/G/T)(A/T), 5, ACTAATA at 4165, ACTAATA at 4158, ACTCACT at 3712, ACTCACA at 3592, ACTAACA at 2678.
	# inverse complement, negative strand, negative direction, looking for (A/T)(C/G/T)A(A/C/G)TCA, 2, ACACTCA at 4094, ATACTCA at 276~~, and complements~~.		# inverse complement, negative strand, negative direction, looking for (A/T)(C/G/T)A(A/C/G)TCA, 2, ACACTCA at 4094, ATACTCA at 276.
	# inverse complement, ~~negative~~ strand, ~~positive~~ direction, looking for (A/T)(C/G/T)A(A/C/G)TCA, 4, ~~ACACTCA~~ at ~~4336~~, ~~TTAATCA~~ at ~~4147~~, ~~AGAGTCA~~ at ~~2613~~, ~~TCAGTCA~~ at ~~2100~~, ~~and complements~~.		# inverse complement, positive strand, negative direction, looking for (A/T)(C/G/T)A(A/C/G)TCA, 5, AGACTCA at 4055, AGAATCA at 3237, AGACTCA at 1404, AGAATCA at 293, AGAATCA at 198.
	# inverse complement, ~~positive~~ strand, ~~negative~~ direction, looking for (A/T)(C/G/T)A(A/C/G)TCA, 5, ~~AGACTCA~~ at ~~4055~~, ~~AGAATCA~~ at ~~3237~~, ~~AGACTCA~~ at ~~1404~~, ~~AGAATCA~~ at ~~293, AGAATCA at 198, and complements~~.		# inverse complement, negative strand, positive direction, looking for (A/T)(C/G/T)A(A/C/G)TCA, 4, ACACTCA at 4336, TTAATCA at 4147, AGAGTCA at 2613, TCAGTCA at 2100.
	# inverse complement, positive strand, positive direction, looking for (A/T)(C/G/T)A(A/C/G)TCA, 3, TTACTCA at 3447, AGACTCA at 3008, AGACTCA at 2952~~, and complements~~.		# inverse complement, positive strand, positive direction, looking for (A/T)(C/G/T)A(A/C/G)TCA, 3, TTACTCA at 3447, AGACTCA at 3008, AGACTCA at 2952.
	# inverse negative strand, negative direction, looking for (A/T)(A/C/G)T(C/G/T)AGT, 5, TCTGAGT at 4055, TCTTAGT at 3237, TCTGAGT at 1404, TCTTAGT at 293, TCTTAGT at 198.		# inverse negative strand, negative direction, looking for (A/T)(A/C/G)T(C/G/T)AGT, 5, TCTGAGT at 4055, TCTTAGT at 3237, TCTGAGT at 1404, TCTTAGT at 293, TCTTAGT at 198.
			# inverse positive strand, negative direction, looking for (A/T)(A/C/G)T(C/G/T)AGT, 2, TGTGAGT at 4094, TATGAGT at 276.
	# inverse negative strand, positive direction, looking for (A/T)(A/C/G)T(C/G/T)AGT, 3, AATGAGT at 3447, TCTGAGT at 3008, TCTGAGT at 2952.		# inverse negative strand, positive direction, looking for (A/T)(A/C/G)T(C/G/T)AGT, 3, AATGAGT at 3447, TCTGAGT at 3008, TCTGAGT at 2952.
	~~# inverse positive strand, negative direction, looking for (A/T)(A/C/G)T(C/G/T)AGT, 2, TGTGAGT at 4094, TATGAGT at 276.~~
	# inverse positive strand, positive direction, looking for (A/T)(A/C/G)T(C/G/T)AGT, 4, TGTGAGT at 4336, AATTAGT at 4147, TCTCAGT at 2613, AGTCAGT at 2100.		# inverse positive strand, positive direction, looking for (A/T)(A/C/G)T(C/G/T)AGT, 4, TGTGAGT at 4336, AATTAGT at 4147, TCTCAGT at 2613, AGTCAGT at 2100.

GLM box gene transcriptions

2026-04-23T09:07:44Z

GCN4 motif samplings

← Older revision		Revision as of 09:07, 23 April 2026
Line 56:		Line 56:

	==GCN4 motif samplings==		==GCN4 motif samplings==
			[[GLM box gene transcriptions#GCN4 motif samplings\|GCN4 motif samplings]]

	Copying an apparent consensus sequence of TGACTCA, TGAGTCA and putting it in "⌘F" finds none located between ZSCAN22 and A1BG and none between ZNF497 and A1BG as can be found by the computer programs. The inverse complement is the same as TGA(C/G)TCA.		Copying an apparent consensus sequence of (r) TGACTCA, TGAGTCA and putting it in "⌘F" finds none located between ZSCAN22 and A1BG and none between ZNF497 and A1BG as can be found by the computer programs. The inverse complement is the same as TGA(C/G)TCA.

	# Negative strand, negative direction: 0.		# Negative strand, negative direction: 0.
Line 63:		Line 64:
	# Negative strand, positive direction: 0.		# Negative strand, positive direction: 0.
	# Positive strand, positive direction: 0.		# Positive strand, positive direction: 0.

			(c) ACTCAGT IDC 0 (2205AB) +21 ACTGAGT +27 (3590AK) -4 ACTGAGT +3 INR-

	==Samplings==		==Samplings==

Sandbox

2026-04-23T00:19:19Z

Medical Treatment of Patients With Thoracic Aortic Disease

← Older revision		Revision as of 00:19, 23 April 2026
(2 intermediate revisions by the same user not shown)
Line 35:		Line 35:
	{\| class="wikitable"		{\| class="wikitable"
	\|-		\|-
	\|[[ACC AHA guidelines classification scheme#Classification of Recommendations\|Class I]]		\|colspan="1" style="text-align:center; background:LightGreen"\|[[ACC AHA guidelines classification scheme#Classification of Recommendations\|Class I]]
	\|-		\|-
	\|"'''1.''' Stringent control of ~~<nowiki>~~[[hypertension]]~~</nowiki>~~, ~~<nowiki>~~[[lipid profile]]~~</nowiki>~~ optimization, <nowiki>[[smoking cessation]]</nowiki>, and other <nowiki>[[atherosclerosis]]</nowiki> risk-reduction measures should be instituted for all patients with <nowiki>[[thoracic aortic aneurysm]]</nowiki> not requiring immediate surgical intervention, as well as for patients who are not considered surgical or stent graft candidates. ''([[ACC AHA guidelines classification scheme#Level of Evidence\|Level of Evidence: C]])''"		\|colspan="1" style="text-align:center; background:LightGreen"\|'''1.''' Stringent control of [[hypertension]], [[lipid profile]] optimization, <nowiki>[[smoking cessation]]</nowiki>, and other <nowiki>[[atherosclerosis]]</nowiki> risk-reduction measures should be instituted for all patients with <nowiki>[[thoracic aortic aneurysm]]</nowiki> not requiring immediate surgical intervention, as well as for patients who are not considered surgical or stent graft candidates. ''([[ACC AHA guidelines classification scheme#Level of Evidence\|Level of Evidence: C]])''"
	\|}		\|}

AGC box gene transcriptions

2026-04-22T21:50:35Z

GCC box samplings

← Older revision		Revision as of 21:50, 22 April 2026
Line 400:		Line 400:

	==GCC box samplings==		==GCC box samplings==
			[[AGC box gene transcriptions#GCC box samplings\|GCC box samplings]]

	Copying GCCGCC in "⌘F" yields one between ZSCAN22 and A1BG and two between ZNF497 and A1BG as can be found by the computer programs.		Copying GCCGCC in "⌘F" yields one between ZSCAN22 and A1BG and two between ZNF497 and A1BG as can be found by the computer programs.

Fractional flow reserve

2026-04-22T21:49:21Z

@@ Line 2: / Line 2: @@
 {{SI}}
-{{CMG}}; '''Associate Editor-In-Chief:''' Priyantha Ranaweera, M.D.
+{{CMG}}; '''Associate Editor-In-Chief:''' Priyantha Ranaweera, M.D. {{ACM}}
 '''''Synonyms and Keywords:''''' FFR, coronary fractional flow reserve
@@ Line 115: / Line 115: @@
 **Pressure wire may track under a plaque and cause a dissection.
 **Repeated attempts in trying to negotiate tortuous anatomy may cause trauma to intact endothelium and promote thrombosis and dissection.
 ==2011, 2009 and 2005 ACCF/AHA/SCAI Guidelines for Percutaneous Coronary Intervention (DO NOT EDIT)<ref name="pmid22070837">{{cite journal|author=Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH |title=2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions |journal=[[Journal of the American College of Cardiology]]|volume=58 |issue=24 |pages=2550–83 |year=2011|month=December|pmid=22070837|doi=10.1016/j.jacc.2011.08.006|url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(11)02875-0|accessdate=2011-12-08|url=http://content.onlinejacc.org/cgi/reprint/58/24/2550.pdf|PDF}}</ref><ref name="pmid19942100">{{cite journal |author=Kushner FG, Hand M, Smith SC, King SB, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO|title=2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines|journal=[[Journal of the American College of Cardiology]]|volume=54|issue=23|pages=2205–41|year=2009|month=December|pmid=19942100|doi=10.1016/j.jacc.2009.10.015|url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(09)03518-9|accessdate=2011-12-06}}</ref><ref name="pmid16490830">{{cite journal| author=Smith SC, Feldman TE, Hirshfeld JW, Jacobs AK, Kern MJ, King SB et al.| title=ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). |journal=Circulation | year= 2006 | volume= 113 | issue= 7 | pages= e166-286 | pmid=16490830 |doi=10.1161/CIRCULATIONAHA.106.173220 | pmc= |url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16490830  }}</ref>==

Sandbox

2026-04-22T17:31:17Z

Thoracic Aortic Aneurysm Medical Therapy ===== Overview ===Medical therapy for patients with a thoracic aortic aneurysm includes aggressive blood pressure control targeting a goal of 130/80 mmHg for all patients, heart rate reduction with beta-

Show changes